Use of CGM in Kidney Transplant Recipients

Part of paid clinical trials in Sacramento, California.

Sponsor
University of California, Davis
Study ID
NCT04783441
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dexcom G6 — DEVICE
    access to continuous glucose monitoring in the Dexcom G6 arm 24/7
  • Dexcom G6 blinded sensor — DEVICE
    retrospective access to continuous glucose profile after 10 days of wear

Study Details

The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.

Key Dates

Start date
Jun 29, 2021
Status verified
Jan 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Active Comparator: Continuous glucose monitoring (CGM)
    Those in the intervention arm will wear a continuous glucose monitoring device. They only need to perform blood glucose fingersticks if the CGM transmission is lost for a prolonged period of time or in cases of hypo- or hyperglycemia when symptoms don't align with blood glucose readings.
  • Placebo Comparator: Self monitoring of blood glucose (fingersticks)
    The control arm will remain on standard-of-care SMBG while the intervention arm will use their CGM. The control arm utilizing SMBG will be required to have at minimum 4 glucose checks per day.

Primary Outcome Measure

Time in Range (70-180 mg/dl) [ Time Frame: 70 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UC Davis HealthSacramentoCalifornia95817
Dahlia Zuidema, PharmD
916-734-4009

Find similar trials in Sacramento, CA

By condition

Related Studies